TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: SCHEDULE Follow Up Visit 5-7 yr

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who participated in the SCHEDULE 12-month main study, and who completed the 3 year follow-up visit~* Patients who are coming for a regular annual clinic visit 5 to 7 years after randomization in the main study~* Obtaining of a separate signed patient informed consent will be required for participation in this follow-up examination.~Exclusion Criteria:~* Patients with a retransplanted heart since the original SCHEDULE study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EVEROLIMUS (Type: EXPERIMENTAL): patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
- Control (Type: ACTIVE_COMPARATOR): patients received standard CsA, MMF and corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with immune thrombocytopenia (ITP) for at least 6 months prior to signing the informed consent form (ICF).~* Subject is ≥ 18 years old while signing the ICF.~* Patients who have no response or relapsed after splenectomy. Or patients who have not been splenectomised and have no response or relapse to at least 1 prior treatment for immune thrombocytopenia (ITP).~* The mean of 3 scheduled platelet counts taken during the screening period must be: \< 30 ×10\^9/L, with none \>35×10\^9/L.~Exclusion Criteria:~* Any known history of bone marrow stem cell disorder. Any abnormal bone marrow findings other than those typical of ITP.~* Any active malignancy. If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, and no treatment or active disease within 5 years prior to signing the ICF..~* Received hematopoietic growth factors (e.g., granulocyte colony-stimulating factor, macrophage colony-stimulating factor, erythropoietin, interleukin-11) for any reason within 4 weeks prior to signing the ICF.~* Received myeloproliferative leukemia (MPL) stimulation product other than the subject who had suspended recombinant human thrombopoietin (rHuTPO) for injection for 4 weeks before signing ICF.~* Received any anti-malignancy agents (e.g., cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, Interferon-alfa) for any reason within 8 weeks prior to signing the ICF.~* Received any monoclonal antibody drugs (e.g., rituximab) for any reason within 14 weeks prior to signing the ICF.~* Less than 4 weeks since end of any clinical trials about therapeutic drug or device prior to signing the ICF.~* Pregnant or breastfeeding.~* In the opinions of the principal investigator or investigators, the patients are not suitable for participation in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received placebo for injection treatment will be administered subcutaneously once a week
- Drug (Type: EXPERIMENTAL): Subjects received Romiplostim for injection treatment will be administered subcutaneously once a week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: eHealth Partnered Evaluation Initiative

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Authenticated My HealtheVet users who have not sent a secure message~* Active patients who have an appointment scheduled in the following year~Exclusion Criteria:~* Authenticated My HealtheVet users who have sent a secure message~* Inactive patients (who do not have an appointment scheduled in the following year)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: Supported Adoption Intervention (SAI) (Type: OTHER): Supported adoption intervention
- Arm 2: General wellness information (Type: ACTIVE_COMPARATOR): General wellness information

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine and Postoperative Depressive Symptom-PASSION

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Brain tumor located supratentorial area and need to receive elective craniotomy;~2. Moderate to severe depressive symptom measured by the qualified psychiatric doctors.~3. Ages between 18 and 65 years old.~4. American Society of Anesthesiologists physical status I-III~Exclusion Criteria:~1. History of epilepsy;~2. Major depression disorder patients undergoing antidepressive therapy within 2 weeks; 3 Psychiatric illness; 4 Drug abuse; 5 History of allergy to the research drug; 6 Tumor located in the Wernick area, Broca area or the frontal pole; 7 Hyperthyroidism; 8 Patients can not cooperate with investigators on psychiatric assessments; 9 Pregnant or breast-feeding woman; 10 refuse to sign inform consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ketamine group (Type: EXPERIMENTAL): None
- normal saline group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intratracheal Budesonide/Surfactant Prevents BPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1) birth Wt 500-1499 gm, 2) respiratory distress shortly after birth and requires resuscitation, 3) failure to NCPAP within 4 hrs after birth, defined as: a) FIO2 ≥ 0.30, pressure \> 5 cmH2O b) severe retraction c) apnea d) PCO2 ≥ 60 mmHg.~Exclusion Criteria:~* 1) lethal cardiopulmonary status, 2) severe congenital anomalies.

- Gender: ALL
- Minimum Age: 30 Minutes
- Maximum Age: 4 Hours
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: ACTIVE_COMPARATOR): Curosurf + budesonide
- Placebo (Type: PLACEBO_COMPARATOR): Curosurf + saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Vaginal Mifepristone to Treat Uterine Fibroids

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Uninterested in fertility during the study.~* Premenopausal status.~* Active symptoms related to uterine fibroids.~* Subjects will be obligated to use non hormonal contraceptives during the study.~Exclusion Criteria:~* Abnormal liver and renal function~* Participants with significant increase in uterine fibroids size during a short time.~* Exclusionary health problems contraindicating mifepristone included adrenal disease; sickle cell anemia; severe liver, respiratory, or renal disease; and blood clotting defect.~* Current use of steroids, anticoagulants, herbals, or botanicals with possible hormonal effects.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 53 Years
- Healthy Volunteers: f

Study Arms:
- antiprogestin (Type: EXPERIMENTAL): Daily use of 10 mg administrated per vagina

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Have been exposed to AVONEX within approximately 1 week of conception or during the first trimester of pregnancy.~* Provide sufficient information to determine that the pregnancy is prospectively registered (i.e., the outcome of pregnancy must be unknown prospectively).~* Provide verbal consent to participate in the Registry.~* Verbally provide contact information for herself, her HCP, and the infant's HCP (if applicable).~NOTE: Other protocol defined inclusion/exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregnant participants (Type: None): Pregnant participants who were exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Kidney transplant recipients under the care of the West London Renal and Transplant Centre~Exclusion Criteria:~* Patients who are unable to give written informed consent~* Simultaneous kidney/pancreas transplant recipients~* Non-heart beating deceased donor transplant recipients~* Patients who would not be offered Campath-1H induction under our current protocol (patients with previous malignancy or with previous exposure to cytotoxic or antiproliferative agents)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Campath-Tacrolimus (Type: ACTIVE_COMPARATOR): Campath induction with 7-day short-course steroids followed by tacrolimus monotherapy
- Daclizumab-Tacrolimus-Mycophenolate (Type: EXPERIMENTAL): Daclizumab induction with 7-day short-course steroids followed by Tacrolimus and Mycophenolate mofetil therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Response in ImmunoCompromised Host. Immune Response After Vaccination Against Pandemic A/H1N1 Influenza

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Above 18 years of age~* Stable antiretroviral regimen or not yet in need of treatment (in case of HIV-infected patients)~Exclusion Criteria:~* Use of systemic immunosuppressive medication~* An ongoing infection~* Recent flu-like symptoms and pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy volunteers (Type: None): Healthy subjects without HIV, vaccinated with Pandemic Influenza A/H1N1
- HIV-infected patients (Type: None): HIV-infected patients, vaccinated with Pandemic Influenza A/H1N1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants who participated in base study P05693 (NCT00697255) and received at least one dose of corifollitropin alfa~* Ongoing pregnancy confirmed by ultrasound at least 10 weeks after bolus injection of hCG in base study P05693~* Able and willing to give written informed consent (informed consent is~incorporated in the informed consent form of protocol P05693)~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- corifollitropin alfa + recFSH Mothers (Type: None): Eligible participants in Stage 1a of base study P05693 (NCT00697255) were administered injection(s) with subcutaneous (SC) corifollitropin alfa (15mcg) and daily SC injections with recFSH (50 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then to be followed for safety and efficacy on the current follow-up (FU) study (P05713) according to standard practice (no treatment administered).
- corifollitropin alfa + hCG Mothers (Type: None): Eligible participants in Stage 1b of base study P05693 (NCT00697255) were administered injection(s) with SC corifollitropin alfa (30 mcg) and daily SC injections with hCG (200 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then followed for safety and efficacy on the current FU study (P05713) according to standard practice (no treatment administered).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have biopsy proven endometrioid adenocarcinoma or adenosquamous carcinoma.~* Patients must have evidence of primary FIGO Stage III-IVB or recurrent endometrial cancer.~* Patients with non-measurable disease following complete cytoreduction at the time of initial operative management for Stage III-IVB are eligible.~* Patients with recurrent disease must have disease confirmed by one of the following:~  1. CT Scan~ 2. MRI~ 3. PET Scan~ 4. Physical Exam~* Patients must have adequate organ function defined as:~  1. Platelets \>/= 100,000/1~ 2. Granulocytes (ANC) \>/= 1,500/~ 3. Creatinine \</= 1.6mg/dl~ 4. SGOT (AST) \</= 3x upper limits of normal~ 5. Bilirubin within institutional normal limits~* Patients must have adequate performance status (ECOG performance status 0-2.~* Patients must be age 19 or greater and have signed informed consent.~Exclusion Criteria:~* Patients with history of other malignancies (except non-melanoma skin cancer or carcinoma-in-situ of the cervix) are ineligible.~* Patients with high-risk histologic subtypes of endometrial cancer, namely papillary serous or clear cell histology are ineligible.~* Patients with evidence of uterine sarcoma, including leiomyosarcoma, carcinosarcoma, endometrial stromal sarcoma, and adenosarcoma are ineligible.~* Patients who are less than 8 weeks after the completion of radiotherapy are ineligible.~* Patients receiving any other investigational agents are ineligible.~* Patients with known hypersensitivity to paclitaxel, carboplatin, or megesterol are ineligible.~* Patients with uncontrolled current illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, serious peripheral neuropathy, or psychiatric illness/social situations that would limit or preclude compliance with study requirements are ineligible.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): Single

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Can Exposure to Brief Messages Correct Misperceptions?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Are established smokers (have smoked at least 100 cigarettes in their lifetime and currently smoke some or all days)~* Are 21 years of age or older (the legal age of tobacco purchase in the US)~* Have not completed the cognitive interview during message pre-testing.~* Rate their agreement with the following statement as at least 50 out of 100: To what extent do you agree with the following statement: The substance nicotine causes cancer.~* Are registered with MTurk in the United States.~* Have completed \>= 5,000 HIITs within the MTurk system~* Have a HIIT approval rating of \>= 97%~Exclusion Criteria:~* Are not established smokers~* Are younger than 21 years of age~* Participated in cognitive interviews during message pre-testing~* Are not registered with MTurk in the US~* Have completed \< 5,000 HIITS~* Have a HIIT approval rating of \<97%~* Rate their agreement with the following statement as less than 50 out of 100: To what extent do you agree with the following statement: The substance nicotine causes cancer.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Nicotine corrective control (Type: ACTIVE_COMPARATOR): A factual message about nicotine that does not contain a causal explanation for what actually causes tobacco-caused disease or an explanation for why the misperception that nicotine causes cancer may have come to be believed.
- Nicotine corrective with causal explanation (Type: EXPERIMENTAL): A factual message about nicotine that contain a causal explanation for what actually causes tobacco-caused disease: tar and chemicals created in tobacco smoke when tobacco is lit on fire.
- Nicotine corrective with reason for misperception (Type: EXPERIMENTAL): A factual message about nicotine that contains an explanation for why the misperception may have come to be believed: that health messaging often discuses nicotine and tobacco-caused disease at the same time and people incorrectly make the connection that nicotine causes cancer.
- Nicotine corrective with both components of coherence (Type: EXPERIMENTAL): A factual message about nicotine that contains both a causal explanation for what actually causes tobacco-caused disease and an explanation for why the misperception may have come to be believed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Increasing Use of Mental Health Services

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60 years and older~* Homebound~* Endorse depressive symptoms~Exclusion Criteria:~* Presence of significant alcohol or substance abuse or psychotic disorder~* High suicide risk, i.e. intent or plan to attempt suicide~* Cognitive impairment~* Inability to speak English~* Aphasia interfering with communication.~* Current use of antidepressants or psychotherapy

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Open Door Intervention (Type: ACTIVE_COMPARATOR): Subjects who receive the Open Door Intervention will work with the study counselor to identify barriers to participation in mental health treatment, set goals, and problem-solve, in addition to receiving a referral.
- Services Referral (Type: NO_INTERVENTION): Subjects who do not receive the Open Door intervention will receive:~1. an evaluation~2. referral to a local mental health provider~3. booklet information on depression and mental health care, and will complete an application for HEAP, a Westchester County service that provides reduced rates from oil companies on heating to seniors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete